8-K: Protara Therapeutics Announces Positive Financial Position and Pipeline Progress in Fourth Quarter and Full Year 2024 Results

Protara Therapeutics reports positive six-month data from the ADVANCED-2 trial, anticipates key milestones in 2025, and boasts a strong cash position extending into 2027.

Summary

• Protara Therapeutics announced its fourth quarter and full year 2024 financial results and provided a business update on March 5, 2025.
• The company reported positive six-month data from the ADVANCED-2 trial of TARA-002 in patients with NMIBC and expects initial data from 12-month evaluable patients by mid-2025.
• Dosing of the first patient in the THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support is expected in the first half of 2025.
• An interim update from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients is expected by the end of the first half of 2025.
• As of December 31, 2024, the company had $170 million in cash, cash equivalents, and investments, which is expected to support planned operations into 2027.
• The net loss for the fourth quarter of 2024 was $12.8 million, or $0.48 per share, compared to a net loss of $10.2 million, or $0.90 per share, for the same period in 2023.
• The net loss for the year ended December 31, 2024, was $44.6 million, or $2.17 per share, compared with a net loss of $40.4 million, or $3.57 per share, for the year ended December 31, 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial positioning, promising clinical trial results, and clear milestones. The increase in R&D expenses is expected for a company in this stage.

Positives

• The company has a strong cash position of $170 million, expected to fund operations into 2027.
• Positive interim results were reported from the ADVANCED-2 trial, with a 72% complete response rate at six months.
• TARA-002 showed a favorable safety profile in the ADVANCED-2 trial, with no Grade 2 or greater treatment-related adverse events.
• The company is on track to initiate the THRIVE-3 registrational trial of IV Choline Chloride in the first half of 2025.
• Protara is on track to provide an interim update on the STARBORN-1 trial of TARA-002 in pediatric patients with LMs by the end of the first half of 2025.

Negatives

• The company incurred a net loss of $12.8 million for the fourth quarter of 2024.
• Research and development expenses increased to $9.5 million for the fourth quarter of 2024, up from $6.4 million in the prior year period.

Risks

• The company's financial guidance may not be as expected.
• There are risks associated with the company's development programs, including clinical trials and regulatory filings.
• The company's ability to obtain sufficient financing to fund its strategic plans and commercialization efforts is a risk.
• Market volatility could impact the company's cash reserves.
• Failure to attract and retain management and key personnel is a risk.

Future Outlook

Protara expects its cash and cash equivalents, and marketable debt securities will be sufficient to fund its planned operations and data milestones into 2027. The company anticipates several key milestones across its development programs in 2025.

Management Comments

• Following a year of significant progress and execution across our pipeline, we remain well positioned to deliver on our mission to bring transformative therapies to patients with cancer and rare diseases, said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics.
• Notably, supported by positive six-month data from our Phase 2 ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC), we continue to believe TARA-002 could represent a differentiated, meaningful addition to the treatment paradigm, both as a monotherapy and in potential combination with other agents.
• With our cash runway extending into 2027, we look forward to achieving many critical milestones across all of our development programs as we work to deliver new treatment options to patients in need.

Industry Context

Protara's focus on NMIBC and lymphatic malformations addresses unmet needs in oncology and rare diseases. The company's TARA-002 program competes with other therapies in development for NMIBC, including checkpoint inhibitors and other immunotherapies. The IV Choline Chloride program targets a specific deficiency in patients on parenteral support, a market with limited treatment options.

Comparison to Industry Standards

• The 72% complete response rate at six months in the ADVANCED-2 trial for TARA-002 in NMIBC patients compares favorably to other intravesical therapies for BCG-unresponsive NMIBC, such as Keytruda (pembrolizumab) which has shown CR rates around 41% at 12 months.
• Chugai Pharmaceutical Co., Ltd. markets OK-432 (Picibanil) in Japan, which is derived from the same master cell bank as TARA-002, providing a benchmark for manufacturing comparability and potential clinical efficacy.
• Companies like Lipella Pharmaceuticals are also developing therapies for NMIBC, and their clinical trial results and regulatory strategies will be important to monitor in comparison to Protara's progress.

Stakeholder Impact

• Shareholders: The positive financial position and clinical trial progress are likely to be viewed favorably by shareholders.
• Patients: The development of new therapies for NMIBC, LMs, and choline deficiency could provide new treatment options for patients in need.
• Employees: The company's strong financial position provides job security and opportunities for growth.
• Creditors: The company's strong cash position reduces the risk of default on debt obligations.

Next Steps

• Report initial data from 12-month evaluable patients in the ADVANCED-2 trial by mid-2025.
• Initiate the THRIVE-3 registrational trial of IV Choline Chloride in the first half of 2025.
• Provide an interim update from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients by the end of the first half of 2025.
• Provide an update on the design of its planned BCG-Nave registrational trial by the end of the first half of 2025.
• Announce interim results from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025.

Key Dates